Ricerc@Sapienza

Objectives: To investigate the long-term safety and efficacy of a treatment switch to dual ART with atazanavir/ ritonavir ! lamivudine versus continuing a standard regimen with atazanavir/ritonavir ! 2NRTI in virologically suppressed patients.
Methods: ATLAS-M is a 96week open-label, randomized, non-inferiority (margin #12%) trial enrolling HIV-infected adults on atazanavir/ritonavir!2NRTI, with stable HIV-RNA ,50copies/mL and CD4 counts .200 cells/mm3. At baseline, patients were randomized 1:1 to switch to atazanavir/ritonavir ! lamivudine or to continue the previous regimen. Here, we report the 96 week efficacy and safety data. The study was registered with ClinicalTrials.gov, number NCT01599364.
Results: Overall, 266 subjects were enrolled (133 in each arm). At 96 weeks, in the ITT population, patients free of treatment failure totalled 103 (77.4%) with atazanavir/ritonavir ! lamivudine and 87 (65.4%) with triple ther- apy (difference !12.0%, 95% CI !1.2/!22.8, P " 0.030), demonstrating the superiority of dual therapy. Two (1.5%) and 9 (6.8%) virological failures occurred in the dual-therapy arm and the triple-therapy arm, respect- ively, without development of resistance to any study drug. Clinical adverse events occurred at similar rates in both arms. A higher frequency of grade 3–4 hyperbilirubinemia (66.9% versus 50.4%, P " 0.006) and hypertrigly- ceridaemia (6.8% versus 1.5%, P " 0.031) occurred with dual therapy, although this never led to treatment dis- continuation. A significant improvement in renal function and lumbar spine bone mineral density occurred in the dual-therapy arm. The evolution of CD4, HIV-DNA levels and neurocognitive performance was similar in both arms.
Conclusions: In this randomized study, a treatment switch to atazanavir/ritonavir ! lamivudine was superior over the continuation of atazanavir/ritonavir ! 2NRTI in virologically suppressed patients, with a sustained bene- fit in terms of improved renal function and bone mineral density.